Fenugreek Compound (N55) Lowers Plasma Glucose through the Enhancement of Response of Physiological Glucagon-like peptide-1

[1]  F. Andreelli,et al.  Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? , 2016, Journal of diabetes research.

[2]  A. Gjedde,et al.  In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial , 2016, Front. Aging Neurosci..

[3]  T. Yada,et al.  Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist , 2016, Journal of diabetes investigation.

[4]  W. Langhans,et al.  Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia , 2015, Diabetes.

[5]  Yu-Hong Cheng,et al.  Isolation of Positive Modulator of Glucagon-like Peptide-1 Signaling from Trigonella foenum-graecum (Fenugreek) Seed* , 2015, The Journal of Biological Chemistry.

[6]  B. Ahrén.  Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes , 2015, Diabetes.

[7]  M. Michael,et al.  Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production , 2014, Diabetes.

[8]  S. Al-Okbi.  Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis , 2014, Toxicology and industrial health.

[9]  I. Idris,et al.  Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. , 2014, Current diabetes reviews.

[10]  F. Giorgino,et al.  GLP-1: benefits beyond pancreas , 2014, Journal of Endocrinological Investigation.

[11]  V. Joshi,et al.  Efficacy and Safety of Standardized Extract of Trigonella foenum‐graecum L Seeds as an Adjuvant to L‐Dopa in the Management of Patients with Parkinson's Disease , 2014, Phytotherapy research : PTR.

[12]  Z. Haouas,et al.  A novel insight on chronic AlCl3 neurotoxicity through IL-6 and GFAP expressions: Modulating effect of functional food fenugreek seeds , 2013, Nutritional neuroscience.

[13]  D. Koya,et al.  Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. , 2013, American journal of physiology. Endocrinology and metabolism.

[14]  M. Donath,et al.  GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine? , 2013, Diabetes Care.

[15]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[16]  A. Tura,et al.  Glucose‐lowering effect of the DPP‐4 inhibitor sitagliptin after glucose and non‐glucose macronutrient ingestion in non‐diabetic subjects , 2013, Diabetes, obesity & metabolism.

[17]  S. Bodhankar,et al.  Neurobehavioral assessment of hydroalcoholic extract of Trigonella foenum-graecum seeds in rodent models of Parkinson’s disease , 2013, Pharmaceutical biology.

[18]  H. Shin,et al.  Antiallergic effect of Trigonella foenum-graecum L. extracts on allergic skin inflammation induced by trimellitic anhydride in BALB/c mice. , 2012, Journal of ethnopharmacology.

[19]  F. Willard,et al.  Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor , 2012, Experimental diabetes research.

[20]  K. Roberts.  The potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemia. , 2011, Journal of medicinal food.

[21]  J. Holst,et al.  Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. , 2011, Endocrinology.

[22]  Francis S. Willard,et al.  Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets , 2010, Diabetes.

[23]  D. Drucker,et al.  Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.

[24]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[25]  S. Woods,et al.  Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake , 2008, Diabetes.

[26]  J. Wylie-Rosett,et al.  Review of Selected Chinese Herbal Medicines in the Treatment of Type 2 Diabetes , 2008, The Diabetes educator.

[27]  R. Seeley,et al.  Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing , 2008, Diabetes.

[28]  J. Holst.  The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[29]  Jeppe Sturis,et al.  Small-molecule agonists for the glucagon-like peptide 1 receptor , 2007, Proceedings of the National Academy of Sciences.

[30]  C. Deacon.  Circulation and Degradation of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[31]  B. Ahrén.  Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[32]  J. Holst,et al.  Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity , 1998, Diabetologia.

[33]  S. Kahn,et al.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. , 1994, The Journal of clinical investigation.

[34]  C. Ørskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis , 1992, Diabetologia.

[35]  O. Chepurny,et al.  Regulation of glucose homeostasis by GLP-1. , 2014, Progress in molecular biology and translational science.

[36]  T. Foltynie,et al.  Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. , 2014, Journal of Parkinson's disease.

[37]  E. Ferrannini,et al.  Direct effect of GLP-1 infusion on endogenous glucose production in humans , 2012, Diabetologia.

[38]  C. Orskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis. , 1992, Diabetologia.